Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Ticker LNTH · Nasdaq · DE
Lantheus Holdings, Inc. is a U.S. business entity operating within the In Vitro & In Vivo Diagnostic Substances sector (SIC 2835). Publicly traded on the Nasdaq under the ticker symbol LNTH, the company is incorporated in Delaware. Based on SEC EDGAR filings, LNTH reported fiscal year 2025 revenue of $1.54B, reflecting a year-over-year growth of 0.5%. Our proprietary Semantic Risk Score of 14 indicates high transparency and low reporting risk, derived from the frequency and consistency of 10-K, 10-Q, and 8-K filing patterns. As part of the SIC 2835 classification, Lantheus Holdings, Inc. serves as a key benchmark for investors and analysts monitoring Delaware corporate performance.
Comparison based on Standard Industrial Classification (SIC) mapping from SEC EDGAR filings.
Filing data sourced from SEC EDGAR signals. 10-K = annual report · 10-Q = quarterly · 8-K = material event.
Lantheus Holdings, Inc. (LNTH) — Key efficiency & solvency metrics · FY2025
Operating Margin
Sector avg: -45.59%
Net Margin
Sector avg: -50.28%
Debt-to-Equity
Sector avg: -0.08
Current Ratio
Sector avg: 4.21
| Key Metric | Company | Industry Avg | Status |
|---|---|---|---|
| Total RevenueYoY: +0.5% | $1.54B | $731.9M | ▲ Outperform |
| Net IncomeYoY: -25.2% | $233.6M | — | — |
| Operating MarginOperating income as % of revenue | 20.2% | -45.59% | ▲ Outperform |
| Net MarginNet income as % of revenue | 15.2% | -50.28% | ▲ Outperform |
| Debt-to-EquityTotal liabilities / stockholders equity. Lower = safer. | 1.04 | -0.08 | ▼ Leveraged |
| Current RatioCurrent assets / current liabilities. Above 1.0 = solvent. | 2.7 | 4.21 | ▼ Lagging |
Source: SEC EDGAR XBRL filings (10-K annual reports). Industry benchmarks derived from 15 companies in SIC 2835.
Disclaimer: All financial data is sourced from raw SEC EDGAR filings. Sprytne.com provides automated data visualization and algorithmic analysis for informational purposes only. This is NOT financial advice, a recommendation to buy/sell, or a guarantee of accuracy. Always verify data via official SEC sources before making investment decisions.
Federal Contracts
TECHNELITE GENERATOR MO99/TC99 5000 MCI, DWIGHT D. EISENHOWER ARMY MEDICAL CENTER (DDEAMC), FORT GORDON, GEORGIA.
TECHNELITE GENERATOR
IFG::CT:IGF FOR CRITICAL FUNCTIONS RADIOLOGY
PYLARIFY
RADIOPHARMACEUTICAL
RADIOPHARMACEUTICAL DIAGNOSTIC PRODUCTS
FDG 18 RADIOPHARMACEUTICAL
200601!600039!2100!W81K02!TRIPLER ARMY MEDICAL CENTER !V797P5763X !C!N! !N!W81K0206F0016!P00002!20051025!20060930!176786812!176786812!001288497!N!BRISTOL-MYERS SQUIBB COMPANY !331 TREBLE COVE RD !NORTH BILLERIC !MA!01862!70400!003!15!TRIPLER ARMY MED CTR!HONOLULU !HAWAII !+000000029932!N!N!000000000000!6505!DRUGS & BIOLOGICALS !C9B!MEDICAL & DENTAL SUPPLIES & EQUIP !000 !NOT DISCERNABLE !325412!E! !6! ! !C! ! !99990909!B! ! ! ! !A! ! ! !000! ! ! ! ! ! ! ! !C!N! ! ! ! ! ! ! !000! ! ! ! ! ! ! ! ! !0001! !
NUCLEAR GENERATORS
CARDIOLITE KITS 5 VIAL KITS
Source: USAspending.gov (Official Federal Award Data). Reflects prime contracts only. Last sync: 2026-03-30.
Compared to 22 peers in In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Revenue
Net Margin
SEC EDGAR XBRL filings by fiscal year
Side-by-side financial showdown — revenue, margins, and growth.
Methodology & compliance note
Data is aggregated from SEC EDGAR and Secretary of State public records. Any analytics such as "market share" are statistical estimates (proxy models) and are not official audits, valuations, or investment advice. Sprytne.com is an independent data aggregator and is not affiliated with any government agency.Learn more →